# info@crystallizationsummit.com

Category : PCS2023

Enabling Green Synthetic Innovations at Merck: Three Examples of Leveraging the Unique Physical Properties of the Solid Phase to Accelerate and Implement Greener Chemical Processes.

By Scott Shultz, Ph.D. Department of Analytical Research and Development, Merck & Co., Inc., Rahway, NJ, USA The role of the crystalline solid phase is often an enabling feature...

Dr. Scott Shultz, Merck & Co.

Scott Shultz has over 20 years of pharmaceutical development experience at Merck in the process and analytical development areas. Since 2008 Scott has led numerous efforts in the materials...

Dr. Haitao Zhang, Sumitomo Pharma America

Haitao Zhang is an Associate Research Fellow in Chemical Development with Sumitomo Pharma America since 2012. In the current role, he is responsible for in developing, and demonstrating commercially...

Development of a scalable atroposelective process to MRTX1719-an inhibitor of the PRMT5*MTA complex

By Cheng Yi Chen, Ph.D. Chemical Processing R&D, Mirati Therapeutics, San Diego, CA 92130, USA chenc@mirati.com A new approach to stereopure atropisomeric molecules is enabled by a continuous flow-crystallization...

Drug Substance Physical Property Control in the Process of Crystallization

By Haitao Zhang, Ph.D. Associate Research Fellow, Sumitomo Pharma America, Inc. The crystallization of active pharmaceutical ingredients, particularly those with multiple polymorphic forms, particle size and morphology critical properties,...

Enabling efficient synthetic route selection by robust purification in crystallization

By Fredrik Nordstrom, Ph.D. Material and Analytical Sciences, Boehringer-Ingelheim, Ridgefield, CT, 06877 fredrik.nordstrom@boehringer-ingelheim.com The decision for selecting and optimizing the synthetic route of a drug candidate is to a...

Dr. Fredrik Nordstrom

Dr. Fredrik Nordstrom leads a solid state and crystallization group within the Material and Analytical Science department at Boehringer-Ingelheim, Ridgefield, CT. The Solid State Chemistry group is responsible for...

Dr. Kaushalendra Chaturvedi (KC), J-Star Research

Dr. Kaushalendra Chaturvedi is a Sr. Research Scientist at J-Star Research Inc., in the Center for Pharma Crystallization (CfPC) and Drug Product Development group (DPD). His research is focused...

Dr. Jian Wang, Ph.D.

Founder, SVP and CTO Center for Pharma Crystallization, J-Star Research ½Porton Pharma Solutions Dr. Jian Wang has 30 years of R&D experience in API crystallization, reaction and process engineering,...

Dr. Harsh S. Shah, J-Star Research

Harsh S. Shah is working as a senior scientist at J-Star Research Inc. (Cranbury, NJ), where he leads “fit-to-purpose” research projects in drug discovery and drug product development. He...

RSS
Follow by Email
LinkedIn
Share